Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles Expressing Plasmodium falciparum Circumsporozoite Epitopes

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Infection and Immunity

• Publication date

  2004-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/IAI.72.11.6519-6527.2004PMID 15501783PMCID PMC523031
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

  2004cited by this paper
• Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi‐immune adults in The Gambia

  2004cited by this paper
• Opsonization by antigen‐specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein‐based vaccine

  2003cited by this paper
• Virus-like particles as immunogens.

  2003cited by this paper
• Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ1

  2003cited by this paper
• A controlled trial of a human papillomavirus type 16 vaccine.

  2002cited by this paper
• A Modified Hepatitis B Virus Core Particle Containing Multiple Epitopes of the Plasmodium falciparum Circumsporozoite Protein Provides a Highly Immunogenic Malaria Vaccine in Preclinical Analyses in Rodent and Primate Hosts

  2002influential reference
• Cutting Edge: A New Tool to Evaluate Human Pre-Erythrocytic Malaria Vaccines: Rodent Parasites Bearing a Hybrid Plasmodium falciparum Circumsporozoite Protein1

  2002cited by this paper
• Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

  2001influential reference
• Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

  2001cited by this paper
• A Totally Synthetic Polyoxime Malaria Vaccine Containing Plasmodium falciparum B Cell and Universal T Cell Epitopes Elicits Immune Responses in Volunteers of Diverse HLA Types1

  2001influential reference
• Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate.

  2001cited by this paper
• Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes.

  2000cited by this paper
• Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

  1999cited by this paper
• CD4+ T-Cell- and Gamma Interferon-Dependent Protection against Murine Malaria by Immunization with Linear Synthetic Peptides from a Plasmodium yoelii17-Kilodalton Hepatocyte Erythrocyte Protein

  1999cited by this paper
• Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

  1998cited by this paper
• Core particles of hepatitis B virus as carrier for foreign epitopes.

  1998cited by this paper
• A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

  1997cited by this paper
• Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy

  1997influential reference
• Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein.

  1997cited by this paper
• Immunization with hybrid hepatitis B virus core particles carrying circumsporozoite antigen epitopes protects mice against Plasmodium yoelii challenge.

  1997cited by this paper
• Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy

  1997cited by this paper
• Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes.

  1996cited by this paper
• Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes.

  1996cited by this paper
• Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

  1995cited by this paper
• Hepatitis B virus core particles as epitope carriers.

  1995cited by this paper
• Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes

  1994cited by this paper
• CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein.

  1993cited by this paper
• T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages.

  1993cited by this paper
• Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers.

  1992cited by this paper
• The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity

  1992cited by this paper
• Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals.

  1991cited by this paper
• Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75.

  1990cited by this paper
• Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75.

  1990cited by this paper
• CD4+ cytolytic T cell clone confers protection against murine malaria

  1990cited by this paper
• Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer.

  1989cited by this paper
• Rationale for the development of an engineered sporozoite malaria vaccine.

  1989cited by this paper
• Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro.

  1987cited by this paper
• Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine.

  1987influential reference
• Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites

  1987influential reference
• Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon.

  1986cited by this paper
• Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies

  1986cited by this paper
• Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum.

  1985cited by this paper
• Sporozoites of mammalian malaria: attachment to, interiorization and fate within macrophages.

  1980cited by this paper
• Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection

  1980cited by this paper
• Antibody-induced ultrastructural changes of malarial sporozoites.

  1976cited by this paper
• Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites.

  1969cited by this paper
• Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

  1967cited by this paper

• EPIclip: A Novel Approach for the Production of Decorated Virus-Like Particles Mediated by High-Affinity Protein Binding Partners.

  2026cites this paper
• Immunogenicity and protection mediated by dmLT and alum adjuvants for an HIV-1 vaccine

  2026cites this paper
• VLP (Virus-Like Particles) Vaccines - Current Knowledge and Future Directions

  2025cites this paper
• A Nanoparticle Comprising the Receptor-Binding Domains of Norovirus and Plasmodium as a Combination Vaccine Candidate

  2025cites this paper
• A synthetic cyclic peptide for promoting antigen presentation and immune activation

  2025cites this paper
• Self-assembling of coiled-coil peptides into virus-like particles: Basic principles, properties, design, and applications with special focus on vaccine design and delivery.

  2024cites this paper
• Glioblastoma vaccines: past, present, and opportunities

  2024cites this paper
• Virus-like Particles in Vaccine Development for Infectious Diseases

  2023cites this paper
• Platforms, advances, and technical challenges in virus-like particles-based vaccines

  2023cites this paper
• Human adenovirus type 7 virus-like particle vaccine induces Dendritic cell maturation through the TLR4/NF-κB pathway and is highly immunogenic.

  2023cites this paper
• Flagellin/Virus-like Particle Hybrid Platform with High Immunogenicity, Safety, and Versatility for Vaccine Development

  2022cites this paper
• Protein-based nanocages for vaccine development.

  2022cites this paper
• Recombinant vaccines in 2022: a perspective from the cell factory

  2022cites this paper
• Protein Cages: From Fundamentals to Advanced Applications.

  2022cites this paper
• Emerging concepts in the science of vaccine adjuvants

  2021cites this paper
• Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers

  2021cites this paper
• Peptide-based supramolecular vaccine systems

  2021cites this paper
• A bivalent antihypertensive vaccine targeting L‐type calcium channels and angiotensin AT1 receptors

  2020cites this paper
• A new approach for therapeutic vaccination against chronic HBV infections.

  2020cites this paper
• Synthesis and Assembly of Hepatitis B Virus-Like Particles in a Pichia pastoris Cell-Free System

  2020cites this paper
• Progress of Gene Therapy in Cardiovascular Disease

  2020cites this paper
• The biomedical and bioengineering potential of protein nanocompartments.

  2020cites this paper
• 4th Applied Synthetic Biology in Europe

  2020cites this paper
• In silico design of a T-cell epitope vaccine candidate for parasitic helminth infection

  2019cites this paper
• Guidelines for Small-Scale Production and Purification of Hepatitis B Surface Antigen Virus-Like Particles from Recombinant Pichia pastoris.

  2019cites this paper
• Plants as sources of natural and recombinant anti-cancer agents.

  2018cites this paper
• Virus-Like Particle Engineering: From Rational Design to Versatile Applications.

  2018cites this paper
• Epitopic Malaria Vaccines Comprised of Minimal T- and B-Cell Epitopes of the P. falciparum CS Protein

  2017cites this paper
• How Plants Can Contribute to the Supply of Anticancer Compounds

  2017cites this paper
• Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.

  2017cites this paper
• Escherichia coli-derived virus-like particles in vaccine development

  2017cites this paper
• High-Yield Production Process of Influenza Virus-Like Particles in Human Cells Toward Large-Scale Vaccine Manufacturing

  2017cites this paper
• Virus-Like Particles

  2017cites this paper
• Pre-Erythrocytic Vaccine Candidates in Malaria

  2016cites this paper
• Enabling Vaccine Delivery Platforms and Adjuvants for Malaria

  2016cites this paper
• Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine

  2016cites this paper
• Big-data-based edge biomarkers: study on dynamical drug sensitivity and resistance in individuals

  2016cites this paper
• Advances and challenges in the development and production of effective plant-based influenza vaccines

  2015cites this paper
• Hepatitis B Hepatitis C virus and Malaria co

  2015cites this paper
• Self-assembling protein nanoparticles in the design of vaccines

  2015influential citation
• Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats

  2015cites this paper
• Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine.

  2014cites this paper
• Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein.

  2014cites this paper
• Advances in nanomedicine towards clinical application in oncology and immunology.

  2014cites this paper
• Subviral particle as vaccine and vaccine platform

  2014cites this paper
• Development of a Chimeric Plasmodium berghei Strain Expressing the Repeat Region of the P. vivax Circumsporozoite Protein for In Vivo Evaluation of Vaccine Efficacy

  2013cites this paper
• Colloidal drug delivery systems in vaccine delivery.

  2013cites this paper
• Hepatitis B core–based virus–like particles to present heterologous epitopes

  2013cites this paper
• Employing an IL-23 p19 vaccine to block IL-23 ameliorates chronic murine colitis.

  2013cites this paper
• A study of recombinant Plasmodium falciparum PFC0760c.

  2013cites this paper
• Carrier molecules for use in veterinary vaccines.

  2013cites this paper
• Development and Evaluation of Chitosan Particle Based Antigen Delivery Systems for Enhanced Antigen Specific Immune Response

  2013cites this paper
• Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

  2013cites this paper
• Chimeric Virus-Like Particle Vaccines Displaying Conserved Enterovirus 71 Epitopes Elicit Protective Neutralizing Antibodies in Mice through Divergent Mechanisms

  2013cites this paper
• Virus-Like Particles as Efficient Delivery Platform to Induce a Potent Immune Response

  2012cites this paper
• A review of malaria vaccine clinical projects based on the WHO rainbow table

  2012cites this paper
• An IL-17 peptide-based and virus-like particle vaccine enhances the bioactivity of IL-17 in vitro and in vivo.

  2012cites this paper
• Innovation in Vaccinology

  2012cites this paper
• Plasmodium falciparum malaria vaccines: current status, pitfalls and future directions

  2012cites this paper
• Progress and Challenges towards the Development of Malaria Vaccines

  2012cites this paper
• Vaccine Design and Vaccination

  2012cites this paper
• HIV p24 as Scaffold for Presenting Conformational HIV Env Antigens

  2012cites this paper
• Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development

  2012influential citation
• Effect of schistosoma infection on malaria immune response: A systematic review

  2011cites this paper
• Longevity and Composition of Cellular Immune Responses Following Experimental Plasmodium falciparum Malaria Infection in Humans

  2011influential citation
• Developments in virus-like particle-based vaccines for infectious diseases and cancer

  2011cites this paper
• Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens

  2011cites this paper
• Targeting IL-12/IL-23 by Employing a p40 Peptide-Based Vaccine Ameliorates TNBS-Induced Acute and Chronic Murine Colitis

  2011cites this paper
• Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses.

  2011cites this paper
• Enhancement of IL-10 bioactivity using an IL-10 peptide-based vaccine exacerbates Leishmania major infection and improves airway inflammation in mice.

  2010cites this paper
• Virus-like particles in vaccine development

  2010cites this paper
• Regulation of CD8+ T cell responses to infection with parasitic protozoa.

  2010cites this paper
• Virus-like particles as particulate vaccines.

  2010cites this paper
• Molecular vaccines for malaria

  2010cites this paper
• Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design

  2010cites this paper
• DEVELOPMENT OF VETERINARY VACCINES

  2010cites this paper
• Targeting TGF‐&bgr;1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis

  2010cites this paper
• THE APPLICATION OF BIOTECHNOLOGY TO THE DEVELOPMENT OF VETERINARY VACCINES

  2010cites this paper
• Targeting IL-12 and/or IL-23 by employing peptide-based vaccines in the amelioration of murine colitis

  2009cites this paper
• Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis.

  2009cites this paper
• Use of hepadnavirus core proteins as vaccine platforms

  2009cites this paper
• Chapter 65 – Malaria

  2009cites this paper
• Aspects of Microparticle Utilization for Potentiation of Novel Vaccines: Promises and Risks

  2009cites this paper
• Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen.

  2009cites this paper
• The coming of age of virus-like particle vaccines

  2008cites this paper
• Phase I Trial of an Alhydrogel Adjuvanted Hepatitis B Core Virus-Like Particle Containing Epitopes of Plasmodium falciparum Circumsporozoite Protein

  2008influential citation
• Nanotechnology in vaccine delivery☆

  2008cites this paper
• codelivery of threshold amounts of plasmid-encoded helper antigen mediated − Enhancement of DNA tumor vaccine efficacy by gene gun

  2008cites this paper
• Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity

  2007cites this paper
• Malaria stage-specific vaccine candidates.

  2007cites this paper
• Therapeutic vaccines: challenges of chronic viral infections

  2007cites this paper
• Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG.

  2007cites this paper
• Virus-like particles: flexible platforms for vaccine development

  2007cites this paper
• Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice.

  2007cites this paper
• Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses

  2006cites this paper
• Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria

  2006cites this paper
• Economic and practical challenges to the formulation of vaccines against endemic infectious diseases such as malaria.

  2006cites this paper
• Developmental Biology of Sporozoite-Host Interactions in Plasmodium falciparum Malaria: Implications for Vaccine Design

  2006cites this paper
• Seroprevalence of malaria in inhabitants of the urban zone of Antananarivo, Madagascar

  2006cites this paper
• A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge

  2006cites this paper